In both studies , there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups ; the difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV@ ranged from @ to @ percentage points ( P < @ ) , which corresponded to a mean relative treatment difference of @ to @ % ( P < @ ) .